FDA Adverse Event Injury Summary report: N

ACTIVA

MDR report key: 13457222 · Received February 4, 2022

Report

Report Number
2182207-2022-00197
Event Type
Injury
Date Received
February 4, 2022
Date of Event
December 7, 2021
Report Date
February 4, 2022
Manufacturer
MEDTRONIC NEUROMODULATION
Product Code
MBX
PMA / PMN Number
P960009
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AS
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

DALIC LJ, WARREN AEL, BULLUSS KJ, ET AL. DBS OF THALAMIC CENTROMEDIAN NUCLEUS FOR LENNOX-GASTAUT SYNDROME (ESTEL TRIAL). ANN NEUROL. 2021.10.1002/ANA.26280. DEEP BRAIN STIMULATION (DBS) IS AN EMERGING TREATMENT FOR PATIENTS WITH LENNOX-GASTAUT SYNDROME (LGS), WITH INCREASING OFF-LABEL USE BASED ON SMALL, OPEN-LABEL STUDIES TARGETING THE CENTRO MEDIAN NUCLEUS OF THALAMUS. ELECTRICAL STIMULATION OF THE THALAMUS IN EPILEPSY OF THE LENNOX-GASTAUT PHENOTYPE) IS THE FIRST RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CM-DBS IN A CAREFULLY CHARACTERIZED COHORT OF YOUNG ADULTS WITH LGS. WE FOUND ALMOST 60% OF STIMULATED PARTICIPANTS HAD A =50% REDUCTION IN ELECTROGRAPHIC SEIZURES COMPARED WITH NONE OF THE CONTROLS, INDICATING A THERAPEUTIC EFFECT OF CM-DBS IN PATIENTS WITH LGS. REPORTED EVENTS 1 PATIENT EXPERIENCED A STAPH-AUREUS INFECTION AFTER AN EDEMA REQUIRING HARDWARE REMOVAL. 1 PARTICIPANT HAD A DROP SEIZURE LEADING TO FACIAL LACERATION, REQUIRING STITCHES UNDER SEDATION. 1 PATIENT EXPERIENCED A SUBDURAL HEMATOMA. IT WAS NOT POSSIBLE TO ASCERTAIN SPECIFIC DEVICE INFORMATION FROM THE ARTICLE OR TO MATCH THE REPORTED EVENT WITH ANY PREVIOUSLY REPORTED EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1316046 ACTIVA MBX MEDTRONIC NEUROMODULATION 37601

Patients

Seq Age Sex Outcome Treatment
1 Female Required Intervention